Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica


-Study... | June 30, 2022

Related Keywords

United States , David Weinstein Naveed Sami , Mark Lebwohl , Maja Koli , Frank Andrews , Matthew Howard , Joana Goncalves , Iris Francesconi , Annie Spinetta , Ralph Bergman , Claudia Zeidler , Nika Franceschi , Annette Dieckh , Ahmed Ansari , Sabine Steinke , Manuelp Pereira , Notalgia Paraesthetica , Lukas Sahhar , Notalgia Paresthetica , Instagram , Linkedin , Twitter , Drug Administration , Nasdaq , Company Annual Report On Form , Exchange Commission , Cara Therapeutics Inc , Oral Difelikefalin , Worst Itch Numeric Rating Scale , Chief Medical Officer , Clinical Therapeutics , Chairman Emeritus , Icahn School , Concept Trial Design , Pruritus Associated , Comparative Observational Study , Clinical Presentation , Chronic Pruritus , Where Have We Been , Curr Derm Rep , Acta Clin Croat , David Weinstein , Dermatological Treatment , Private Securities Litigation Reform Act , Cara Therapeutic , Annual Report , Cara Therapeutics , Nc Stock Exchange , News , Information , Press Release , Lara , Herapeutics , Nnounces , Positive , Topline , Results , Rom , Comfort , Hase , , Trial , F , Mural , Difelikefalin , Or , The , Treatment , Pruritus , N , Patients , Ith , Otalgia Cara Us1407551092 ,